Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 245

Similar articles for PubMed (Select 21690228)

1.

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.

Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A, O'Regan RM.

Mol Cancer Ther. 2011 Aug;10(8):1460-9. doi: 10.1158/1535-7163.MCT-10-0925. Epub 2011 Jun 20.

2.

Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.

Williams CB, Soloff AC, Ethier SP, Yeh ES.

Adv Cancer Res. 2015;127:253-81. doi: 10.1016/bs.acr.2015.04.008. Epub 2015 May 8.

PMID:
26093903
3.

Death-associated protein kinase 1 promotes growth of p53-mutant cancers.

Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH.

J Clin Invest. 2015 Jul 1;125(7):2707-20. doi: 10.1172/JCI70805. Epub 2015 Jun 15.

PMID:
26075823
4.

Therapeutic Targets of Triple Negative Breast Cancer: A Review.

Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N.

Br J Pharmacol. 2015 Jun 4. doi: 10.1111/bph.13211. [Epub ahead of print]

PMID:
26040571
5.

Identification of epidermal growth factor receptor and its inhibitory microRNA141 as novel targets of Kr├╝ppel-like factor 8 in breast cancer.

Li T, Lu H, Mukherjee D, Lahiri SK, Shen C, Yu L, Zhao J.

Oncotarget. 2015 May 27. [Epub ahead of print]

6.

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ.

Br J Cancer. 2015 Jun 9;112(12):1895-903. doi: 10.1038/bjc.2015.163. Epub 2015 May 26.

PMID:
26010411
7.
8.

Anti-PD-L1 for metastatic triple-negative breast cancer.

Gibson J.

Lancet Oncol. 2015 Jun;16(6):e264. doi: 10.1016/S1470-2045(15)70208-1. Epub 2015 Apr 30. No abstract available.

PMID:
25936988
9.

Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?

Klinke DJ 2nd.

Breast Cancer Res. 2014 Nov 7;16(6):457. doi: 10.1186/s13058-014-0457-z. No abstract available.

10.

Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.

Wang YL, Overstreet AM, Chen MS, Wang J, Zhao HJ, Ho PC, Smith M, Wang SC.

Oncotarget. 2015 May 10;6(13):11150-61.

11.

Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.

Borges S, Perez EA, Thompson EA, Radisky DC, Geiger XJ, Storz P.

Mol Cancer Ther. 2015 Jun;14(6):1306-16. doi: 10.1158/1535-7163.MCT-14-0945. Epub 2015 Apr 7.

PMID:
25852060
12.

Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.

Wang JG, Yu J, Hu JL, Yang WL, Ren H, Ding D, Zhang L, Liu XP.

Cell Signal. 2015 Jul;27(7):1315-24. doi: 10.1016/j.cellsig.2015.03.015. Epub 2015 Mar 26.

PMID:
25817575
13.

Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.

Vogel RI, Coughlin K, Scotti A, Iizuka Y, Anchoori R, Roden RB, Marastoni M, Bazzaro M.

Oncotarget. 2015 Feb 28;6(6):4159-70.

14.

Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts.

Ding XF, Yin DQ, Chen Q, Zhang HY, Zhou J, Chen G.

Tumour Biol. 2015 Mar;36(3):1463-9. doi: 10.1007/s13277-014-2580-y. Epub 2015 Mar 7.

PMID:
25744729
15.

Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.

Zuo M, Rashid A, Churi C, Vauthey JN, Chang P, Li Y, Hung MC, Li D, Javle M.

Br J Cancer. 2015 Mar 17;112(6):1042-51. doi: 10.1038/bjc.2014.625.

PMID:
25742482
16.

Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo.

Rytelewski M, Buensuceso A, Leong HS, Deroo BJ, Chambers AF, Koropatnick J.

J Vis Exp. 2015 Feb 6;(96). doi: 10.3791/52388.

PMID:
25741641
17.

The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.

Wan X, Zheng X, Pang X, Zhang Z, Jing T, Xu W, Zhang Q.

Int J Pharm. 2015 Apr 30;484(1-2):16-28. doi: 10.1016/j.ijpharm.2015.02.037. Epub 2015 Feb 17.

PMID:
25700543
18.

PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.

Brady SW, Zhang J, Tsai MH, Yu D.

Cancer Biol Ther. 2015;16(3):402-11. doi: 10.1080/15384047.2014.1002693.

PMID:
25692408
19.

Study Illuminates How Cancers Evade EGFR Inhibitors.

[No authors listed]

Cancer Discov. 2015 Apr;5(4):OF1. doi: 10.1158/2159-8290.CD-NB2015-023. Epub 2015 Feb 13.

PMID:
25680713
20.

Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review.

Taylor S, Lam M, Pararasa C, Brown JE, Carmichael AR, Griffiths HR.

Cancer Cell Int. 2015 Jan 24;15(1):1. doi: 10.1186/s12935-015-0156-6. eCollection 2015.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk